Clinical Trial: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.

U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07117474) titled 'Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.' on July 09.

Brief Summary: To evaluate the safety and tolerability of a single subcutaneous injection of HRS-9563 in hypertensive subjects

Study Start Date: Dec. 24, 2024

Study Type: INTERVENTIONAL

Condition: Subjects With Mild Hypertension

Intervention: DRUG: HRS-9563, placebo

A single subcutaneous injection of HRS-9563 injection or placebo was administered

Recruitment Status: RECRUITING

Sponsor: Fujian Shengdi Pharmace...